TRVI
Trevi Therapeutics, Inc.
Healthcare — Biotechnology
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Price History
Fundamentals
| Market Cap | $2.52B |
| P/E Ratio (TTM) | - |
| Forward P/E | -31.78 |
| EPS (TTM) | $-0.32 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -33.59% |
| Debt/Equity | 0.40 |
| Recommendation | None |
| Analyst Target | $23.90 |
| Analysts | 10 |
| Next Earnings | Aug 6, 2026 AMC |
| Indexes | - |
Technical Indicators
| RSI (14) | 80.4 |
| Beta | 1.05 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $19.26 |
| 52-Week Low | $5.71 |
| 50-Day Avg | $14.87 |
| 200-Day Avg | $12.22 |
| Avg Volume | $1.82M |
| Volume | 20.5K |
Performance Analysis
NEUTRALTRVI presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:35 UTC
Back to Screener Export Report